News | March 14, 2022
Applications for PLI in bulk drugs extended till March 31st 2022
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers releases guidelines for the scheme
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
